Peter Finn

4.7k total citations · 2 hit papers
33 papers, 3.5k citations indexed

About

Peter Finn is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Pharmacology. According to data from OpenAlex, Peter Finn has authored 33 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Cardiology and Cardiovascular Medicine, 8 papers in Surgery and 5 papers in Pharmacology. Recurrent topics in Peter Finn's work include Cardiovascular Function and Risk Factors (12 papers), Heart Failure Treatment and Management (10 papers) and Cardiac pacing and defibrillation studies (6 papers). Peter Finn is often cited by papers focused on Cardiovascular Function and Risk Factors (12 papers), Heart Failure Treatment and Management (10 papers) and Cardiac pacing and defibrillation studies (6 papers). Peter Finn collaborates with scholars based in United States, United Kingdom and Israel. Peter Finn's co-authors include Marc A. Pfeffer, Scott D. Solomon, John J.V. McMurray, Ernest T. Hawk, Janet Wittes, Monica M. Bertagnolli, Ann G. Zauber, Robert Fowler, William F. Anderson and Karl Swedberg and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Peter Finn

32 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

2005 1.6k citations Scott D. Solomon, John J.V. McMurray et al. profile →
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients

2015 302 citations Akshay S. Desai, John J.V. McMurray et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Finn United States	21	1.7k	1.5k	565	346	315	33	3.5k
Robert Fowler United States	7	516 0.3×	1.7k 1.2×	510 0.9×	345 1.0×	336 1.1×	10	2.7k
Bettina Oxenius United States	6	501 0.3×	1.6k 1.1×	524 0.9×	227 0.7×	323 1.0×	9	2.4k
James A. Bolognese United States	31	1.1k 0.6×	3.3k 2.2×	1.3k 2.4×	658 1.9×	548 1.7×	71	5.7k
Francesca Catella-Lawson United States	11	1.3k 0.8×	2.1k 1.4×	518 0.9×	245 0.7×	716 2.3×	15	3.1k
Antonio González‐Pérez Spain	27	618 0.4×	877 0.6×	678 1.2×	366 1.1×	81 0.3×	69	2.8k
Giulia Renda Italy	27	1.9k 1.1×	610 0.4×	746 1.3×	539 1.6×	129 0.4×	111	3.5k
N M Agrawal United States	10	634 0.4×	2.2k 1.5×	734 1.3×	163 0.5×	342 1.1×	24	2.8k
Aimee Burr United States	7	603 0.4×	2.1k 1.4×	626 1.1×	152 0.4×	340 1.1×	10	2.7k
Stan Heptinstall United Kingdom	36	2.4k 1.4×	650 0.4×	846 1.5×	662 1.9×	167 0.5×	129	4.3k
John G. Fort United States	21	749 0.4×	1.4k 0.9×	1.0k 1.8×	78 0.2×	293 0.9×	65	2.6k

Countries citing papers authored by Peter Finn

Since Specialization

Citations

This map shows the geographic impact of Peter Finn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Finn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Finn more than expected).

Fields of papers citing papers by Peter Finn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Finn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Finn. The network helps show where Peter Finn may publish in the future.

Co-authorship network of co-authors of Peter Finn

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Finn. A scholar is included among the top collaborators of Peter Finn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Finn. Peter Finn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vaduganathan, Muthiah, Jonathan W. Cunningham, Brian Claggett, et al.. (2021). Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction. JACC Heart Failure. 9(5). 374–382. 25 indexed citations

Desai, Akshay S., John G.F. Cleland, Muthiah Vaduganathan, et al.. (2020). MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND LEFT VENTRICULAR EJECTION FRACTION≥45%: INSIGHTS FROM PARAGON-HF. Journal of the American College of Cardiology. 75(11). 998–998. 1 indexed citations

Weinrauch, Larry A., Brian Claggett, Jiankang Liu, et al.. (2018). Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. International Journal of Nephrology and Renovascular Disease. Volume 11. 155–164. 21 indexed citations

Bajaj, Navkaranbir S., Brian Claggett, Eldrin F. Lewis, et al.. (2017). INFLUENCE OF LEFT VENTRICULAR EJECTION FRACTION ON CAUSE-SPECIFIC MORTALITY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE TOPCAT TRIAL. Journal of the American College of Cardiology. 69(11). 884–884. 2 indexed citations

Weinrauch, Larry A., John A. D’Elia, Matthew R. Weir, et al.. (2017). Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial. International Journal of Nephrology and Renovascular Disease. Volume 10. 233–242. 3 indexed citations

Weinrauch, Larry A., John A. D’Elia, Peter Finn, et al.. (2016). Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study). Diabetes Research and Clinical Practice. 113. 143–151. 10 indexed citations

Jhund, Pardeep S., John J.V. McMurray, Nish Chaturvedi, et al.. (2015). Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. European Heart Journal. 36(36). 2463–2469. 28 indexed citations

Charytan, David M., Eldrin F. Lewis, Akshay S. Desai, et al.. (2015). Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases. 66(3). 429–440. 26 indexed citations

Desai, Akshay S., John J.V. McMurray, Milton Packer, et al.. (2015). Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal. 36(30). 1990–1997. 302 indexed citations breakdown →

10.

Ye, Siqin, Jens Jakob Thune, Hajime Uno, et al.. (2011). Circumstances and Outcomes of Sudden Unexpected Death in Patients With High-Risk Myocardial Infarction. Circulation. 123(23). 2674–2680. 13 indexed citations

11.

Kenchaiah, Satish, Peter Finn, Jordi Soler‐Soler, et al.. (2010). Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American Heart Journal. 160(1). 145–151. 28 indexed citations

12.

Kenchaiah, Satish, Stuart Pocock, Duolao Wang, et al.. (2007). Body Mass Index and Prognosis in Patients With Chronic Heart Failure. Circulation. 116(6). 627–636. 304 indexed citations

13.

Solomon, Scott D., Marc A. Pfeffer, John J.V. McMurray, et al.. (2006). Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas. Circulation. 114(10). 1028–1035. 206 indexed citations

14.

Janardhanan, Rajesh, Satish Kenchaiah, Eric J. Velazquez, et al.. (2006). Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. American Heart Journal. 152(1). 183–189. 17 indexed citations

15.

Solomon, Scott D., Bertil Olofsson, Peter Finn, et al.. (2004). 1069-113 Cause of death across full spectrum of ventricular function in patients with heart failure: The CHARM study. Journal of the American College of Cardiology. 43(5). A180–A180. 2 indexed citations

16.

Solomon, Scott D., et al.. (1999). Temporal dissociation of left ventricular function and remodeling following experimental myocardial infarction in rats. Journal of Cardiac Failure. 5(3). 213–223. 29 indexed citations

17.

Opitz, Christian, Peter Finn, Marc A. Pfeffer, Gary F. Mitchell, & Janice M. Pfeffer. (1998). Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage. Journal of the American College of Cardiology. 32(1). 261–267. 31 indexed citations

18.

Mitchell, Gary F., Marc A. Pfeffer, Peter Finn, & Janice M. Pfeffer. (1997). Comparison of techniques for measuring pulse-wave velocity in the rat. Journal of Applied Physiology. 82(1). 203–210. 48 indexed citations

19.

Mitchell, Gary F., Marc A. Pfeffer, Peter Finn, & Janice M. Pfeffer. (1996). Equipotent Antihypertensive Agents Variously Affect Pulsatile Hemodynamics and Regression of Cardiac Hypertrophy in Spontaneously Hypertensive Rats. Circulation. 94(11). 2923–2929. 57 indexed citations

20.

Cooper, Christopher B., Janice M. Pfeffer, Peter Finn, & Marc A. Pfeffer. (1995). Characteristics of a model of myocardial infarction produced by coronary artery ligation in the rat. Cardiovascular Pathology. 4(3). 189–194. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact